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Abstract
Rationale Vortioxetine is a novel multimodal antidepressant
that is a 5-HT1B receptor partial agonist, a 5-HT1A receptor
agonist, an inhibitor of the serotonin (5-HT) transporter, and a
5-HT1D, 5-HT3, and 5-HT7 receptor antagonist in vitro. In vivo
studies have shown that vortioxetine enhances levels of 5-HT
and desensitizes 5-HT1A autoreceptors.
Objectives The aim of the present study was to investigate the
effects of acute and long-term administration of vortioxetine
on the terminal 5-HT1B receptor and the tonic activation of 5-
HT1A receptor in the rat hippocampus.
Methods These receptors were assessed following vortioxetine
administration acutely or subcutaneously using minipumps for
14 days. These studies were carried out using in vivo electro-
physiological recording, microiontophoresis, and stimulation
of the ascending 5-HT fibers.
Results Vortioxetine enhanced the inhibitory effect of the
stimulation of the 5-HT bundle at a high, but not low frequen-
cy and reversed the inhibitory effect of the 5-HT1B receptor
agonist CP 94253. These results indicate that this compound
acted as a 5-HT1B receptor partial agonist. Vortioxetine
inhibited 5-HT reuptake but did not dampen the sensitivity
of postsynaptic 5-HT1A receptors on pyramidal neurons.
Long-term administration of vortioxetine and escitalopram
(both at 5 mg/kg/day) induced an increase of tonic activation
of the 5-HT1A receptors in CA3 pyramidal neurons, resulting
in an increase in 5-HT transmission. In addition, vortioxetine
decreased the function of terminal 5-HT1B autoreceptor
following its sustained administration.
Conclusions Desensitization of 5-HT1B autoreceptor and an
increase of tonic activation of 5-HT1A receptors in the
hippocampus may contribute to the antidepressant effect of
vortioxetine.
Keywords Electrophysiology . Serotonin . Hippocampus .
Vortioxetine . Escitalopram . 5-HT1A receptor . 5-HT1B
receptor
Introduction
Clinical studies have established that vortioxetine is an effec-
tive antidepressant with a potential benefit on cognitive func-
tions (Citrome 2014;McIntyre et al. 2013; Alvarez et al. 2014;
Katona et al. 2012; Mahableshwarkar et al. 2014). In preclin-
ical studies, vortioxetine displays two modes of pharmacolog-
ical action on the serotonin (5-hydroxytryptamine, 5-HT) sys-
tem: it selectively blocks the 5-HT transporter (5-HTT) and
binds with moderate to high affinity to human (h) 5-HT1A, 5-
HT1B, 5-HT1D, 5-HT3, and 5-HT7 receptors (Mørk et al.
2012). In vitro, it is a full agonist at 5-HT1A receptors, a partial
agonist at 5-HT1B receptors, and an antagonist at 5-HT1D, 5-
HT3, and 5-HT7 receptors.
A previous electrophysiological study showed that acute
administration of vortioxetine potently suppresses the firing
rate of dorsal raphe (DR) 5-HT neurons without optimally
occupying the 5-HTT (Bétry et al. 2013). This is unlikely to
result from a direct activation of the somatodendritic 5-HT1A
autoreceptors because vortioxetine has an affinity about 30
times lower for the rat (r)5-HT1A receptor than for the 5-
HTT (Mørk et al. 2012; Pehrson et al. 2013). Consequently,
this marked suppression of firing may be due to the enhanced
synaptic 5-HT availability resulting from synergy between 5-
HTT inhibition and activation of receptor(s), as it is reversed
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by the selective 5-HT1A receptor antagonist WAY-100635
(Bétry et al. 2013). Another action of vortioxetine on 5-HT
neuronal firing distinguishes it from selective 5-HT reuptake
inhibitors (SSRIs): during its sustained administration in rats,
the (r)5-HT1A autoreceptor is already desensitized and the
firing rate of 5-HT neurons returns to control level within
3 days (Bétry et al. 2013). In contrast, the firing rate of 5-HT
neurons returns to normal after 2 to 3 weeks of administration
of SSRIs, which is also due to 5-HT1A autoreceptor desensi-
tization (Blier and de Montigny 1983; Czachura and Rasmus-
sen 2000; El Mansari et al. 2005).
A unique property of vortioxetine is its affinity for 5-HT1B
receptors; in vitro, it appears to act as a partial agonist (Mørk
et al. 2012). Such receptors are located on 5-HT terminals,
where they exert an inhibitory action on 5-HT release, and
postsynaptically as well. Importantly, in vitro and in vivo ap-
proaches have shown that the terminal 5-HT1B autoreceptors
desensitize following long-term administration of SSRIs
(Blier and Bouchard 1994; Chaput et al. 1986, 1991;
Dremencov et al. 2002). This adaptive change leads to a great-
er release of 5-HT for each impulse reaching 5-HT terminals,
thus contributing to the enhancement of 5-HT transmission in
the presence of SSRIs (Blier and El Mansari 2013).
The first goal of this study was to provide in vivo evidence
for the partial agonistic action of vortioxetine on the terminal
(r)5-HT1B autoreceptor. The second was to determine whether
vortioxetine could enhance 5-HT1A transmission in the hippo-
campus using a regimen producing a suboptimal inhibition of
the 5-HTT. Indeed, a 3-day administration of vortioxetine
(5 mg/kg/day) resulted in only 41% occupancy of (r)5-HTT
(Mørk et al. 2012). It was also shown that a daily dose of
10 mg of vortioxetine in humans is effective in major depres-
sive disorder but only results in about 50% occupancy of 5-
HTTs, in contrast to minimal effective doses of SSRIs, which
produce about 80% 5-HTT occupancy (Areberg et al. 2012;
Meyer et al. 2004; Stenkrona et al. 2013). Finally, this study
was aimed at assessing the function of the terminal 5-HT1B
receptor following its long-term activation with vortioxetine.
Materials and methods
Animals
Adult male Sprague–Dawley rats (Charles River, Saint-
Constant, QC, Canada) weighing 250–350g at the time of
the experiments were used. Animals were housed two per
cage under standard laboratory conditions (12:12-h light/
dark cycle; light cycle start at 7:00am; temperature 21±1°C,
40–50% relative humidity) with access to food and water ad
libitum. All animals were handled in accordance with the
guidelines of the Canadian Council on Animal Care and the
local animal care committee of the University of Ottawa In-
stitute of Mental Health Research (Ottawa, Canada).
Drug administration
Rats were anesthetized with isoflurane to implant the osmotic
Alzet minipumps (Durect, Palo Alto, CA, USA), which deliv-
ered vehicle, vortioxetine subcutaneously at a dose of 5 mg/kg/
day for 2 or 14 days, or escitalopram at a dose of 5 mg/kg/day
for 14 days. These doses were selected on the basis of previ-
ous electrophysiological studies (Bétry et al. 2013).
Extracellular recording and microiontophoresis of CA3 dorsal
hippocampus pyramidal neurons
Rats were anesthetized with chloral hydrate (400 mg/kg, i.p.)
and mounted in a stereotaxic apparatus. Supplemental doses
of chloral hydrate (50-100 mg/kg, i.p.) were given to prevent
any nociceptive reaction to tail or hind paw pinch. A burr hole
was drilled at specific stereotaxic coordinates for the defined
region for recordings, and neurons were identified by their
spike shape, duration, and frequency. Neuronal activity was
recorded in real time using the Spike2 software (Cambridge
Electronic Design, Cambridge, UK), which was also used for
analysis offline the electrophysiological characteristics of neu-
rons. Body temperature was maintained at 37°C throughout
the experiments using a thermistor-controlled heating pad. A
catheter was inserted in the lateral tail vein for intravenous
injections of pharmacological agents.
Extracellular recording and microiontophoresis were per-
formed with five-barreled glass micropipettes in CA3 region
of the hippocampus. The central barrel, used for the unitary
recording, was filled with a 2 M NaCl solution, and the imped-
ance of these electrodes ranged from 2 to 4 MΩ. The side
barrels were filled with the following solutions: 5-HT creati-
nine sulfate (10 mM in 200 mM NaCl, pH 4), quisqualic acid
(1.5mM in 200mMNaCl, pH 8), and the last barrel with a 2M
NaCl solution used for automatic current balancing. The mi-
cropipette was lowered into the dorsal hippocampus CA3 re-
gion using the following coordinates: 4mm anterior to lambda
and 4.2 mm lateral (Paxinos and Watson 1998). A small cur-
rent of quisqualate was used to activate the pyramidal neurons
within their physiological firing range (10 to 15 Hz; Ranck
1973) because these neurons do not discharge spontaneously
in chloral hydrate anesthetized rats. The hippocampus CA3
pyramidal neurons are found at a depth of 4.0 mm below the
surface of the brain and identified by their large amplitude
(0.5–1.2 mV) and long-duration (0.8–1.2 ms) simple action po-
tentials, alternating with complex spike discharges (Kandel
and Spencer 1961). 5-HT was microiontophoretically applied
for 50-s periods with a current of 20 nA. The duration of local
5-HTapplication and ejection currents (nA) was kept constant
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before and after each intravenous (i.v.) injection of the 5-HT1A
receptor antagonist WAY-100635.
In vivo determination of the sensitivity of 5-HT1A receptors
In rat that received vehicle or vortioxetine, pyramidal neuron
responsiveness to the microiontophoretic application of 5-HT
was quantified by means of the IT50 index (nC), i.e., the
current (nA) multiplied by the time (s) required to obtain
50% inhibition of spontaneous firing rate of pyramidal neu-
rons (Brunel and de Montigny 1988).
In vivo determination of 5-HT uptake
In order to assess the relative degree to which vortioxetine
(5 mg/kg/day) and escitalopram (5 mg/kg/day) blocks the 5-
HTT, t h e RT50 va lu e s we r e de t e rm ined a f t e r
microiontophoretic application of 5-HT (20 nA for 50 s) in hip-
pocampus CA3 region. The RT50 values correspond to the
time (s) elapsed from the cessation of microiontophoretic ap-
plication of 5-HT to 50% recovery of the initial firing rate
(Fig. 3; Pineyro et al. 1994). It is a reliable index of the 5-
HT reuptake process in vivo. Indeed, previous experiments
showed that administration of the SSRIs escitalopram and
paroxetine (both 10 mg/kg/day) increased by threefold the
RT50 values (El Mansari et al. 2005; Pineyro et al. 1994).
Furthermore, the same degree of prolongation of the RT50
value was also observed in rats after lesion of 5-HT neurons,
thereby eliminating 5-HTT (Pineyro et al. 1994).
The 5-HT pathway stimulation
The CA3 region of hippocampus receives extensive projections
from the median and DR 5-HT neurons. In order to electrically
stimulate the ascending 5-HT pathway, a bipolar electrode (NE-
100, David Kopf, Tujunga, CA, USA) was implanted 1mm
anterior to lambda on the midline with a 10° backward angle
in the ventromedial tegmentum and 8.0±0.2mm below the sur-
face of the brain. Two hundred square pulses with duration of
0.5 ms were delivered by a stimulator (S48, Grass Instruments,
West Warwick, RI, USA) at an intensity of 300 μA and a fre-
quency of 1 and 5 Hz. The stimulation of the 5-HT pathway
induces a brief suppressant period due to the release of 5-HT
into the synapse. The effects of stimulation of the ascending 5-
HT pathway were assessed to determine the function of termi-
nal 5-HT1B autoreceptors (Chaput et al. 1986, 1991; Blier and
de Montigny 1994). The two series of 300 stimulation pulses
delivered at 1 and 5 Hz were carried out because previous stud-
ies showed that activation of terminal 5-HT1B autoreceptors
decreases 5-HT release in the terminal areas and that increasing
the frequency of stimulation from 1 to 5 Hz induces a greater
activation of 5-HT1B autoreceptors, and consequently a greater
negative feedback on the release of 5-HT (Chaput et al. 1986,
1991). As a result, the smaller release of the neurotransmitter in
the synapse obtained at 5 Hz induces a shorter period of sup-
pression compared to that obtained at 1 Hz. The stimulation
pulses and the firing activity were analyzed by computer using
Spike 2 software (Cambridge Electronic Design Limited, UK).
Peristimulus time histograms (PSTH) of CA3 pyramidal neu-
rons were generated to determine the suppression of firing mea-
sured as duration of suppression of firing (DOS in millisec-
onds). DOS is defined as the time interval initiated by a 50%
reduction in the number of events per bin from the mean
prestimulation probability of firing, to the time it returned to
90% of that same prestimulation value.
Determination of the tonic activation of 5-HT1A receptor
in the hippocampus
In order to assess the degree of activation of the 5-HT1A re-
ceptors exerting an inhibitory influence on the firing activity
of CA3 pyramidal neurons, the selective 5-HT1A receptor an-
tagonist WAY-100635 was administered intravenously to dis-
inhibit these neurons resulting in an increase of their firing
activity (Haddjeri et al. 1998). The disinhibition would be best
determined if the neurons were not firing at a high rate; there-
fore, their firing rate was decreased by reducing the ejection
current of quisqualate, and after a baseline activity, the selec-
tive 5-HT1A receptor antagonist WAY-100635 (25–100 μg/kg)
was injected intravenously afterward. It can be assumed that
any increment in the firing activity of hippocampus pyramidal
neurons would reflect an increased level in the tonic activation
of the 5-HT1A receptors, and the degree to which WAY-
100635 disinhibit this firing would be a direct measure of
the tonic level of activation of these receptors by extracellular
5-HT. The percent change of firing activity was assessed by
calculating the mean firing rate of neurons from about 2min
prior to and after i.v. administrations of the drug.
Drug injections
In the acute studies, every neuron was examined by the whole
sequence of drugs (Figs. 1 and 2). Only one neuron was tested
per rat to avoid residual effects. At least 1min lasted after drug
i.v. injection before the start of stimulation.
Drugs
Vortioxetine and escitalopram were provided by Lundbeck.
WAY-100635, 5-HT creatinine sulfate, and chloral hydrate
were purchased from Sigma (St. Louis, MO, USA).
Quisqualic acid and CP 94253 were purchased from Tocris
(Ellisville, MO, USA). Vortioxetine and CP 94253 were dis-
solved in 20% hydroxypropyl-beta-cyclodextrin.
Escitalopram was dissolved in a 0.9% NaCl solution. WAY-
100635 was dissolved in distilled water.
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Data analysis
The data are presented as mean values ± SEM. Statistical com-
parisons were carried out using a one-way or Kruskal-Wallis
one-way ANOVA on ranks followed by Dunn’s method. Drug
administration and stimulation (1 vs 5 Hz) were used as main
factors, and statistical analyses of the data were done with two-
way repeated measures analysis of variance (ANOVA), follow-
ed for all pairwise multiple comparisons by the Tukey LSD
post hoc analysis. Statistical significance was taken as P<0.05.
Results
Effect of the acute administration of vortioxetine on 5-HT1B
receptor activation in the hippocampus
In order to examine the net effect of vortioxetine on terminal 5-
HT1B autoreceptor activation by electrically evoked release of
endogenous 5-HT, the effectiveness of two series of stimula-
tions was delivered at different frequencies while recording
from same pyramidal neuron. Indeed, the higher the frequency
Fig. 1 Assessment of the effect
of vortioxetine by itself on
terminal 5-HT1B autoreceptors in
the hippocampus. Peristimulus
time histograms illustrating
effects of stimulation (1 vs 5 Hz)
of the ascending 5-HT pathway
on the firing activity of CA3 py-
ramidal neurons before (control;
a) and following the i.v. adminis-
tration of vortioxetine (b; 6 mg/
kg). Hence, after 1- and 5 Hz
stimulations were completed,
vortioxetine was injected follow-
ed at least 1 min after by 1 and
5 Hz stimulations in the same rat
(n=6). ***P<0.001 compared to
control; N.S. non-significant dif-
ference. DOS is the duration of
suppression (ms) of the firing of
pyramidal neurons induced by
endogenous 5-HT following
stimulation of the 5-HT bundle
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of stimulation is, greater should be the degree of activation of
the terminal autoreceptor. Consequently, the smaller release of
the neurotransmitter in the synapse obtained at 5 Hz induces a
shorter period of suppression compared to that obtained at 1Hz.
First, when the effect of vortioxetine per se was tested
(Fig. 1), a two-way ANOVAwith repeated measures showed
a significant effect of the stimulation (F[1, 22]=9.5; P<0.05)
and a significant interaction factor (stimulation × drug admin-
istration F[1, 22]=9.2; P<0.05). The Tukey post hoc test
showed that in control, 5-HT-induced inhibition of pyramidal
neurons was significantly decreased after stimulation with
5 Hz when compared to 1 Hz stimulation (P<0.05; n=6),
whereas this inhibition was no longer statistically significant
between 1 and 5 Hz, following i.v. administration of
vortioxetine to the same rat (P>0.05). Taken together, these
results suggest that vortioxetine blocked the activation of 5-
HT1B receptors. It showed also that vortioxetine did not en-
hance the efficacy of the stimulation at 1 Hz when tested on
same neuron (P>0.05; Fig. 1), as a 5-HT1B receptor antago-
nist such as methiotepin would normally do (Chaput et al.
1986), showing that vortioxetine is not a pure antagonist.
In the second series of experiments (Fig. 2), the effect of
vortioxetine was tested following activation of the 5-HT1B
receptors by the potent and selective 5-HT1B receptor agonist
CP 94253. A two-way ANOVAwith repeated measures on the
inhibition resulting from endogenous 5-HT release following
electrical stimulation revealed a significant effect of
vortioxetine (F[2, 33]=4.7; P<0.05) and stimulation (F[2,
33]=75.6; P<0.001), as well as a significant interaction (stim-
ulation×drug treatment; F[2, 33]=6.4; P<0.05). Using Tukey
post hoc test and as previously reported in naive rats (Chaput
et al. 1986, 1991), the 5-HT-induced inhibition of the firing
activity of pyramidal neurons following 5 Hz stimulations was
significantly shorter than with stimulation at 1 Hz (P<0.001;
n=6; Fig. 2). This effect has been shown to be due to an
increase in activation of the terminal 5-HT1B receptor stem-
ming from an increase in 5-HT release in its immediate
biophase during stimulation at 5 Hz. Following i.v. adminis-
tration of CP 94253 (2 mg/kg) to the same rat, the duration of
the inhibition at both 1 and 5 Hz stimulations was significantly
shorter compared to pre-injection condition (P<0.05; n=6;
Fig. 2), indicating an overactivation of 5-HT1B receptors by
this agonist. When vortioxetine (6 mg/kg) was i.v. injected
after CP 93253, there was no significant difference between
the effects of stimulation with 1 and 5 Hz (P>0.05; n=6;
Fig. 2). This suggests that while vortioxetine is able to reverse
the effect of a potent 5-HT1B receptor agonist, it acted as a 5-
HT1B receptor partial agonist.
In vivo 5-HTT blockade properties of vortioxetine
In order to measure reuptake inhibition by vortioxetine, the
RT50 value was determined. Ejection of 5-HT at a current
of 20 nA for 50s was kept constant and yielded an 80 to
100% inhibition of CA3 pyramidal neurons firing. Since
the RT50 value is better determined when neurons are
completely inhibited, only those responding with 100% in-
hibition were considered for RT50 analysis (Fig. 3). The
mean RT50 for control rats administered with vehicle was
24±3s (n=12) and increased to 52±4s in rats treated for
14 days with vortioxetine (n=10) and to 51±9s in rats that
received a suboptimal dose of escitalopram for 14 days (n=
11; Kruskal-Wallis one-way ANOVA on ranks followed by
Dunn’s method; P<0.001 for both drugs compared to vehi-
cle). The significant enhancement in the RT50 indicates a
blockade of 5-HT reuptake transporters in the CA3 region
of the hippocampus in rats that received vortioxetine or
escitalopram..
Sensitivity of 5-HT1A receptors on pyramidal neurons
of the CA3 region of the hippocampus
IT50 values were determined as a measure of postsynaptic 5-
HT1A receptor sensitivity. As shown in Fig. 3, there was no
alteration in sensitivity of the 5-HT1A receptors, when 5-HT
was microiontophoretically applied at currents of 20 nA (IT50
values for control (n=12), 48 nC±4; 14-day vortioxetine
Fig. 2 Assessment of the effect of vortioxetine (6 mg/kg) on the
hippocampus terminal 5-HT1B autoreceptor following its activation by
the 5-HT1B receptor agonist CP 94253 (2 mg/kg). Peristimulus time
histograms showing effects of stimulation of the ascending 5-HT pathway
(1 - 5 Hz) on the firing activity of pyramidal neuron in control, followed at
least 1min after by i.v. injection of CP 94253 and then i.v. administration
of vortioxetine on the same neuron. Only one neuron was tested per rat
(n=6). *P<0.05; **P<0.01; ***P<0.001. N.S. non-significant differ-
ence. #P<0.05, significant difference in DOS determined at 5 Hz follow-
ing administration of CP 94253 when compared to controls. DOS is the
duration of suppression (ms) of the firing of pyramidal neurons induced
by endogenous 5-HT following stimulation of the 5-HT bundle
Psychopharmacology (2015) 232:2343–2352 2347
(n=10), 60 nC±6; escitalopram (n=8), 45 nC±7 (one-way
ANOVA; P>0.05)). This result showed that sensitivity of
the 5-HT1A receptors on CA3 pyramidal neurons was not
changed after administration of these drugs.
Effect of vortioxetine on the tonic activation of the 5-HT1A
receptor in the dorsal hippocampus
The effect of WAY-100635 on the quisqualate-activated firing
activity of CA3 pyramidal neurons was assessed in rats that
received vehicle, vortioxetine, and escitalopram for 14 days
(Fig. 4). A two-way ANOVA (followed by Tukey post hoc
test) on tonic activation of 5-HT1A receptors in CA3 pyrami-
dal neurons revealed a significant effect of drug treatment with
vortioxetine and escitalopram ([F2, 73]=12.9, P<0.001), and
WAY-100635 (F[2, 73]=20.4, P<0.001), and a significant
interaction between both variables (F[2, 73]=4.7, P<0.001).
Following sustained administration of vortioxetine and
escitalopram, the tonic activation of the 5-HT1A receptors by
WAY-100635 was significantly enhanced compared to the ve-
hicle group, reaching 141 and 197%, respectively, at a dose of
100μg/kg (Fig. 4; vehicle group, n=8; vortioxetine group, n=
6; escitalopram group, n=5). However, there was no signifi-
cant difference between the vortioxetine and escitalopram
groups.
Assessment of the sensitivity of terminal 5-HT1B
autoreceptors
In order to determine if long-term administration of
vortioxetine altered 5-HT1B receptor responsiveness, rats were
administered vehicle and vortioxetine for 14 days and electri-
cal stimulation of the ascending 5-HT bundle was preformed
(Fig. 5). Since vortioxetine has a strong affinity for the 5-HT1B
receptor, a decreased efficacy of electrical stimulation could
be explained by either desensitization of the 5-HT1B
autoreceptor or competition between endogenous 5-HT and
vortioxetine. For this reason, a 24-h washout period (consid-
ering a plasma elimination half-life of only 3.2-h; Mørk et al.
2012) was used to discount the second explanation of de-
creased electrical stimulation efficacy. Although the effect
on 5-HT-induced inhibition of pyramidal neurons was not
statistically significant following 14 days of vortioxetine ad-
ministration (two-way ANOVAwith repeated measures; F[1,
23]=0.7; P>0.05), the goal in these experiments was to deter-
mine if the decrease usually observed in control group follow-
ing stimulations with 5 Hz is still present in the vortioxetine-
treated animals. Interestingly, a significant effect of interaction
Fig. 3 Integrated firing rate histograms of quisqualate (QUIS)-activated
pyramidal neuron illustrating blockade of 5-HT transporters, as measured
with RT50 index in rat that received vehicle (a; n=12), vortioxetine (b;
5 mg/kg/day; n=10), and escitalopram (c; 5 mg/kg/day; n=11) for 14 days.
The RT50 values correspond to the time in seconds elapsed from the
cessation of microiontophoretic application of 5-HT (horizontal gray
bar) to 50% recovery of the initial firing rate (indicated by a dashed
arrow). d Note the increase in RT50 in rats that were administered with
vortioxetine and escitalopram when compared to vehicle group.
***P<0.001 compared to control
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(P<0.05; F[1, 21]=5.1; two-way ANOVAwith repeated mea-
sures) and stimulation (P<0.05; F[1, 21]=24.6) was revealed
following Tukey post hoc test. It showed that 5-HT-induced
inhibition of pyramidal neurons was significantly decreased
after stimulation with 5 Hz when compared to 1 Hz in vehicle-
treated rats (P<0.05; n=6; Tukey post hoc test) and that this
difference is no longer statistically significant between 1 and
5 Hz in rats that received vortioxetine for 14 days (P>0.05; n=
7; Tukey post hoc test). This indicates that 14-day administra-
tion of vortioxetine resulted in desensitization of terminal 5-
HT1B autoreceptors in the hippocampus.
Discussion
The present study showed that vortioxetine acted as a 5-HT1B
receptor partial agonist because it competed with both an
exogenous 5-HT1B receptor agonist and endogenous 5-HT
under high but not low degree of activation of the terminal
5-HT1B autoreceptor. It also showed that vortioxetine in-
creased tonic activation of 5-HT1A receptors on pyramidal
neurons in the hippocampus resulting from enhanced 5-HT
levels, because there was no change of the sensitivity of these
postsynaptic 5-HT1A receptors. Long-term vortioxetine ad-
ministration also produced a desensitization of 5-HT1B
autoreceptors located on 5-HT terminals in the hippocampus.
Acute administration of vortioxetine had no effect on 5-HT-
induced inhibition when the ascending 5-HT bundle was stim-
ulated at a frequency of 1 Hz. If vortioxetine was acting as a
pure 5-HT1B receptor agonist, it should have reduced the sup-
pression duration of firing as was found with the 5-HT1B re-
ceptor agonist CP 94253. Had vortioxetine been acting as a
pure antagonist, this inhibition would have at least doubled at
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Fig. 4 Integrated firing rate histograms of quisqualate (QUIS)-activated
pyramidal neuron showing its responsiveness to the microiontophoretic
application of 5-HT and i.v. injection of WAY-100635 in vehicle-treated
rats (a; n=8) and rats administered for 14 days with vortioxetine (b; 5 mg/
kg/day; n=6) and escitalopram (c; 5 mg/kg/day; n=5). Note the increase
in firing activity of pyramidal neurons after the injection of WAY-100635
(b and c compared to a), after which the inhibitory effect of 5-HT was
blocked. d Degree (%±SEM) of increase of the firing activity of
pyramidal neurons after the administration of WAY-100635, in control
rats and those administered with vortioxetine and escitalopram for
14 days. In each rat, only one neuron was tested. **P<0.01 and
##P<0.01. N.S. non-significant difference
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receptor antagonist methiotepin (Chaput et al. 1986). However,
after the acute administration of vortioxetine and the
overactivation of 5-HT1B autoreceptors using 5-Hz stimula-
tions, the decrease in inhibition was no longer significant
(Fig. 1). Therefore, these results indicate that vortioxetine was
acting as a 5-HT1B receptor partial agonist, since it only com-
peted with high levels of endogenous 5-HT, resulting from the
higher frequency of stimulation. This property of vortioxetine
was also reported in recombinant cell lines which showed that
vortioxetine acts as a partial agonist at 5-HT1B receptors (Mørk
et al. 2012). Moreover, vortioxetine displays a partial agonistic
activity at the h5-HT1B receptor when measured in whole cell
based cAMP assay (Mørk et al. 2012). It is noteworthy that the
above mentioned acute effects of vortioxetine were not due to
its 5-HT reuptake blocking property. Indeed, a previous study
showed that acute administration of the SSRI citalopram,
which completely suppresses the firing activity of 5-HT neu-
rons, resulted in no alteration of the suppression of firing activ-
ity of CA3 pyramidal neurons from stimulation of the ascend-
ing 5-HT pathway (Chaput et al. 1986).
The present study confirmed previous results showing that
the effect of iontophoresed 5-HT on pyramidal neurons is
mainly via 5-HT1A receptors as this effect was reversed by
the selective 5-HT1A receptor antagonist WAY-100635
(Fig. 4; El Mansari et al. 2005; Haddjeri et al. 1998). As
reported herein, the 14-day administration of vortioxetine
did not significantly change the sensitivity of 5-HT1A recep-
tors on CA3 pyramidal neurons, in line with previous studies
with SSRIs (El Mansari et al. 2005) and 5-HT1A receptor
agonist such as gepirone (Haddjeri et al. 1998). It is worth
noting that these 5-HT1A receptors have nevertheless the ca-
pacity to desensitize as was shown following sustained mono-
amine oxidase A inhibition using the antidepressant clorgyline
(Blier et al. 1986).
The current experiments were deemed to have been carried
out in the presence of suboptimal 5-HTT inhibition. Indeed,
the RT50 values obtained with both vortioxetine and
escitalopram (both at 5 mg/kg/day, s.c.) administered by os-
motic minipumps were doubled compared to controls. How-
ever, several reports from our group have shown that this
index of in vivo reuptake is tripled in rats with lesioned 5-
HT neurons to eliminate 5-HTT (Pineyro et al. 1994), and
with regimens of 10 mg/kg/day of either escitalopram or par-
oxetine (El Mansari et al. 2005; Pineyro et al. 1994). Interest-
ingly, the latter regimen of escitalopram produces in rats plas-
ma levels similar to those observed in humans using therapeu-
tic doses (10–20 mg/day; Bourke et al. 2013).
In the present study, a 14-day administration of
vortioxetine and escitalopram (both at 5 mg/kg/day) produced
an enhancement in the tonic activation of the 5-HT1A receptor
that is typical of SSRIs tested (see Blier and ElMansari 2013).
Since the responsiveness of postsynaptic 5-HT1A receptors on
pyramidal neurons was unaltered, this enhancement must
therefore be attributable to an elevation of synaptic 5-HT in
their vicinity, as vortioxetine shows a very weak affinity for 5-
HT1A receptors in rats when compared to humans (Bang-An-
dersen et al. 2011; Mørk et al. 2012). Interestingly, in micro-
dialysis studies, subchronic (3 days) administration of
vortioxetine at this same dose (5 mg/kg/day) significantly el-
evated extracellular levels of 5-HT in ventral hippocampus
(Mørk et al. 2012), although only 41% of 5-HTT was occu-
pied when this dose is used. Interestingly, vortioxetine admin-
istration resulted in an increase in tonic activation of the 5-
HT1A receptors in the hippocampus that was similar to that
seen with suboptimal dose of escitalopram, as shown in the
present study. Furthermore, the effect of vortioxetine on tonic
activation of 5-HT1A receptors may be underestimated be-
cause, unlike in humans, this compound possesses a low af-
finity for 5-HT1A and 5-HT7 receptors in rats (Bang-Andersen
et al. 2011; Mørk et al. 2012). This is all the more important
since previous studies showed that 5-HT1A receptor agonists
(e.g., gepirone; Haddjeri et al. 1998) and the 5-HT7 receptor
antagonist SB269970 (Mnie-Filali et al. 2011) by increasing
5-HT transmission (Wesołowska et al. 2006) induced a robust
enhancement of the tonic activation of 5-HT1A receptors in the
hippocampus (Blier and El Mansari 2013).
This increase in 5-HT transmission can be due, at least in
part, to the attenuated function of the terminal 5-HT1B
Fig. 5 Effect of sustained administration of vortioxetine (5 mg/kg/day)
on the responsiveness of terminal 5-HT1B autoreceptors in the
hippocampus. Peristimulus time histograms illustrating effects of
stimulation of the ascending 5-HT pathway on the firing activity of
CA3 pyramidal neurons in vehicle rats that received hydroxypropyl-
beta-cyclodextrin (n=6) and those that received vortioxetine for 14 days
(n=7), followed by a 24-h period of washout (to ascertain that the
autoreceptor is desensitized and not blocked). DOS is the duration of
suppression of the firing of pyramidal neurons induced by endogenous
5-HT following 5-HT bundle stimulation. Only one neuron was tested in
each vehicle- or vortioxetine-administered rat. ***P<0.001. N.S. non-
significant difference
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autoreceptor. Indeed, the present results showed that fol-
lowing sustained administration of vortioxetine, this
autoreceptor appeared to be desensitized since the differ-
ence in the efficacy of the 1 and 5 Hz stimulation was also
no longer significant after a vortioxetine washout. In
in vivo and brain slice experiments, long-term administra-
tion of various SSRIs was shown to induce a desensitization
of the terminal 5-HT1B autoreceptors that account for the
increased effectiveness of 5-HT synaptic transmission in
the rat hippocampus (Blier and Bouchard 1994; Chaput
et al. 1986, 1991; Moret and Briley 1990). Previous studies
showed that the concomitant blockade of SERTand 5-HT1B
receptors increases the extracellular 5-HT levels in the hip-
pocampus (de Groote et al. 2003). Moreover, the selective
5-HT1B/1D receptor antagonist GR127935, which by itself
did not alter basal 5-HT levels, doubled them in animals
when 5-HTT was blocked using fluoxetine or paroxetine
(Gobert et al. 1997; Sharp et al. 1997). Interestingly,
vortioxetine was also shown to increase levels of 5-HT
more in the ventral hippocampus than in the medial pre-
frontal cortex (Pehrson et al. 2013) most likely by acting
on several receptors, rather than just blocking the 5-HTT
(Mørk et al. 2012; Pehrson et al. 2013).
In conclusion, vortioxetine blocks the 5-HTT but does
not dampen the sensitivity of postsynaptic 5-HT1A recep-
tors. Long-term vortioxetine administration increases the
tonic activation of the postsynaptic 5-HT1A receptor in the
hippocampus, an effect common to all antidepressants stud-
ied strategies so far. In addition, vortioxetine decreased the
function of the terminal 5-HT1B autoreceptor under a high
but not a low degree of activation, thus showing that it acts
as a partial agonist. This study has shown that vortioxetine
exerts several different actions on the serotonergic system in
the hippocampus, which can in part explain the action of
vortioxetine as an effective antidepressant in the clinic (Al-
varez et al. 2014). Furthermore, to these properties, previ-
ous preclinical studies have shown that vortioxetine is
endowed with many properties that were shown to be in-
volved in antidepressant action. Hence, vortioxetine is a 5-
HT7 receptor antagonist, an h5-HT1A receptor agonist, and a
5-HT3 receptor antagonist (Mørk et al. 2012; see also
Pehrson and Sanchez 2014). Vortioxetine also showed anti-
depressant and anxiolytic-like effects in behavioral models
(Guilloux et al. 2013).
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